Abstract
Background
Since it has been observed that melanocytic lesions can alter their appearance during pregnancy, we analyzed whether hormone receptors are expressed in conjunctival nevi as well as conjunctival melanoma. We further analyzed whether the number of estrogen (ER) or progesterone receptors (PR) might be associated with the disease course in conjunctival melanoma.
Methods
Twenty-seven paraffin-embedded samples of conjunctival nevi and 27 conjunctival melanoma specimens were examined using immunohistological analysis with antibodies against PR and ER. The percentage of stained cells were analyzed, taking into account patient gender and age. Out of the melanoma group, all patients with complete data for tumor thickness, tumor localization, age at diagnosis, gender, and follow-up including recurrence, metastasis and tumor-related death were included in the second part of the study (n = 15), where hormone receptor rates were associated with tumor outcome, regarding recurrences, metastasis or death. Written consent was received from all included patients.
Results
Both nevi and melanomas showed high rates of PR- and ER-positive cells. In Nevi, 64 ± 25 % of cells stained positive for PR and 35 ± 34 % for ER. In melanoma specimens, 68 ± 30 % showed PR and 44 ± 34 % ER expression. Differences between men and women in expression rates were not statistically significant. Out of 15 melanoma patients (nine female, six male), 53 % (five women and three men) experienced 1—4 recurrences, and four patients developed metastases. The median estimated survival time was 12.2 years. A multivariate survival model taking into account known risk factors for prognosis in conjunctival melanoma confirmed tumor location to be an important predictive factor for outcome (p = 0.05). The rate of PR or ER did not show a statistically significant correlation with the disease course in our cohort.
Conclusions
We observed that conjunctival melanocytic lesions express hormone receptors, which could explain why these tumors can alter their appearance under hormonal changes. Regarding the prognosis of conjunctival melanoma, no statistically significant correlation between hormone receptor expression and event-free survival was found in this analysis.
Similar content being viewed by others
References
Tuomaala S, Eskelin S, Tarkkanen A, Kivelä T (2002) Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. IOVS 43:3399–3408
Yu G-P, Hu D-N, McCormick S, Finger PT (2003) Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 135:800–806
Damato B, Coupland SE (2009) Management of conjunctival melanoma. Expert Rev Anticancer Ther 9:1227–1239
Shields CL (2000) Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Trans Am Ophthalmol Soc 98:471–492
Shildkrot Y, Wilson MW (2010) Conjunctival melanoma: pitfalls and dilemmas in management. Curr Opin Ophthalmol 21:380–386
Anastassiou G, Heiligenhaus A, Bechrakis N, Bader E, Bornfeld N, Steuhl K-P (2002) Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol 86:163–167
Missotten GS, Keijser S, Keizer RJWD, Wolff-Rouendaal DD (2005) Conjunctival melanoma in the Netherlands: a nationwide study. IOVS 46:75–82
Gallagher RP, Elwood JM, Hill GB, Coldman AJ, Threlfall WJ, Spinelli JJ (1985) Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada Melanoma Study. Br J Cancer 52:901–907
Lea CS, Holly EA, Hartge P, Lee JS, Guerry D, Elder DE, Halpern A, Sagebiel RW, Tucker MA (2007) Reproductive risk factors for cutaneous melanoma in women: a case–control study. Am J Epidemiol 165:505–513
Driscoll MS, Grant-Kels JM (2006) Nevi and melanoma in pregnancy. Dermatol Clin 24:199–204
Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P, Lottici R, Papadia F, Sofra MC, Bacchi M (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516–523
Gans LA, Lee SF, Lemp MA, Pepose JS (1990) Estrogen and progesterone receptors and human conjunctiva. Am J Ophthalmol 109:474–477
Esmaeli B, Harvey JT, Hewlett B (2000) Immunohistochemical evidence for estrogen receptors in meibomian glands. Ophthalmology 107:180–184
Bonini S, Lambiase A, Schiavone M, Centofanti M, Palma LA, Bonini S (1995) Estrogen and progesterone receptors in vernal keratoconjunctivitis. Ophthalmology 102:1374–1379
Wickham LA, Gao J, Toda I, Rocha EM, Ono M, Sullivan DA (2000) Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol Scand 78:146–153
Fuchsjäger-Mayrl G, Nepp J, Schneeberger C, Sator M, Dietrich W, Wedrich A, Huber J, Tschugguel W (2002) Identification of estrogen and progesterone receptor mRNA expression in the conjunctiva of premenopausal women. IOVS 43:2841–2844
Vavilis D, Agorastos T, Vakiani M, Jafetas J, Panidis D, Konstantinidis T, Bontis J (1997) The effect of transdermal estradiol on the conjunctiva in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 72:93–96
Pache M, Glatz-Krieger K, Sauter G, Meyer P (2006) Expression of sex hormone receptors and cell cycle proteins in melanocytic lesions of the ocular conjunctiva. Graefes Arch Clin Exp Ophthalmol 244:113–117
Foss AJ, Alexander RA, Guille MJ, Hungerford JL, McCartney AC, Lightman S (1995) Estrogen and progesterone receptor analysis in ocular melanomas. Ophthalmology 102:431–435
Paridaens DA, Alexander RA, Hungerford JL, McCartney AC (1991) Oestrogen receptors in conjunctival malignant melanoma: immunocytochemical study using formalin fixed paraffin wax sections. J Clin Pathol 44:840–843
Spelsberg H, Klueppel M, Reinhard T, Glaeser M, Niederacher D, Beckmann MW, Sundmacher R (2004) Detection of Oestrogen receptors (ER) α and β in conjunctiva, lacrimal gland, and tarsal plates. Eye 18:729–733
Auw-Haedrich C, Feltgen N (2003) Estrogen receptor expression in meibomian glands and its correlation with age and dry-eye parameters. Graefes Arch Clin Exp Ophthalmol 241:705–709
Werschnik C, Lommatzsch PK (2002) Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol 25:248–255
Damato B, Coupland SE (2009) An audit of conjunctival melanoma treatment in Liverpool. Eye 23:801–809
Conflict of interest
The authors declare that they have no conflicts of interest relevant to this study.
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have full control of all primary data and they agree to allow Graefes Archive for Clinical and Experimental Ophthalmology to review their data upon request.
Rights and permissions
About this article
Cite this article
Bredow, L., Stützel, L., Böhringer, D. et al. Progesterone and estrogen receptors in conjunctival melanoma and nevi. Graefes Arch Clin Exp Ophthalmol 252, 359–365 (2014). https://doi.org/10.1007/s00417-013-2523-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-013-2523-0